...We Welcome You To The Resverlogix HUB withIn The AGORACOM COMMUNITY!

Free
Message: RESVERLOGIX EXCEEDS FULL ENROLLMENT FOR THE PIVOTAL PHASE 3 BETONMACE CLINICAL TRIAL

 "We are exploring the option of US enrollment in the BETonMACE trial as well as the option of relying on existing BETonMACE data to file a US New Drug Application (NDA)."

Hmmmmm. All that work to get FDA approval for inclusion of US patients in BETonMACE and now this? Interesting.....

Share
New Message
Please login to post a reply